Hims & Hers Health CEO Andrew Dudum has publicly rejected a lawsuit filed by the U.S. Federal Trade Commission against the telehealth company, arguing that regulators fundamentally misunderstand how its platform operates.
The FTC’s action targets the company’s business practices, though Dudum framed the legal challenge as a byproduct of the firm’s role in shaking up traditional healthcare and pharmaceutical markets. “We are active disruptors,” Dudum said, defending the company’s model against the regulatory scrutiny.
Hims & Hers has expanded aggressively in recent years, moving from its origins in men’s wellness products into weight-loss treatments, including compounded versions of GLP-1 drugs, a class of medications used to manage obesity and diabetes. The company has also leaned heavily on artificial intelligence to streamline consultations and prescriptions.
Compounded GLP-1 medications have become a flashpoint across the telehealth sector, as demand for weight-loss drugs has surged while branded supplies from major pharmaceutical manufacturers have fluctuated. Compounding pharmacies produce alternative formulations, a practice that has drawn increasing regulatory attention.
Dudum contended that the FTC’s case rests on a misreading of the company’s structure and the way its telehealth and subscription services function. He said the lawsuit fails to account for the operational realities of a platform that connects patients with licensed providers.
The dispute arrives during a volatile stretch for the company. Its push into weight-loss treatments has pressured profit margins even as revenue has climbed, reflecting the costs of scaling into a competitive and heavily regulated market.
Hims & Hers has invested in leadership and infrastructure to support that growth, and the company maintains that its approach expands access to care and lowers costs for consumers who have historically faced barriers within conventional healthcare systems.
The FTC has not detailed the full scope of its allegations publicly, and the case is likely to hinge on how courts interpret the boundaries between telehealth platforms, compounding pharmacies, and consumer protection law.
The outcome could carry broader implications for the fast-growing telehealth industry, where AI-driven prescribing and compounded medications have outpaced existing regulatory frameworks. A resolution is expected to take months as both sides prepare their arguments.